Blood test may speed up chemo decisions for deadly pancreatic cancer
NCT ID NCT07096362
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing whether a blood test that looks for tumor DNA (ctDNA) can tell doctors within weeks if chemotherapy is shrinking a patient's pancreatic cancer. Currently, doctors wait about 8 weeks for a scan to see if treatment is working. The trial will enroll 50 people with metastatic pancreatic cancer who are starting their first chemotherapy. If the blood test shows the cancer is not responding, doctors may switch treatments earlier than usual.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
5-Fluorouracil, Oxaliplatin, Leucovorin (chemotherapy drugs)
What this could lead to
If successful, this could show that a simple blood test can help doctors decide sooner whether to switch chemotherapy for pancreatic cancer, potentially improving outcomes.
What could go wrong
This is a small, early-phase study (50 people) testing a new use of an existing test. The blood test may not reliably predict treatment response, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••